Legend Biotech Past Earnings Performance
Past criteria checks 0/6
Legend Biotech's earnings have been declining at an average annual rate of -29.2%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 33% per year.
Key information
-29.2%
Earnings growth rate
-18.8%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 33.0% |
Return on equity | -41.4% |
Net Margin | -181.8% |
Next Earnings Update | 13 May 2024 |
Recent past performance updates
Recent updates
Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)
Mar 15Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?
Mar 06Legend Biotech: Solid Traction With Carvykti Rollout
Jan 29Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up
Jan 16Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?
Nov 09Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?
Apr 12An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued
Dec 14Legend Biotech wins approval of Carvykti for multiple myeloma in Japan
Sep 27Legend Biotech stock slides on proposed ADS offering
Jul 25Legend Biotech ends Phase 1 trial for lymphoma candidate
Jul 07News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts
Jun 05Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?
May 14Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results
Mar 22Legend Biotech: Carvykti Approval Makes For A Buy Opportunity
Mar 04Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be
Mar 03Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?
Dec 30Calculating The Intrinsic Value Of Legend Biotech Corporation (NASDAQ:LEGN)
Nov 22Is Legend Biotech (NASDAQ:LEGN) Using Debt Sensibly?
Aug 26Analysts Have Just Cut Their Legend Biotech Corporation (NASDAQ:LEGN) Revenue Estimates By 18%
Jun 11Revenue & Expenses BreakdownBeta
How Legend Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 285 | -518 | 201 | 0 |
30 Sep 23 | 233 | -509 | 191 | 0 |
30 Jun 23 | 165 | -532 | 184 | 0 |
31 Mar 23 | 103 | -526 | 180 | 0 |
31 Dec 22 | 117 | -446 | 174 | 0 |
30 Sep 22 | 106 | -416 | 192 | -227 |
30 Jun 22 | 96 | -457 | 181 | -155 |
31 Mar 22 | 119 | -346 | 161 | 313 |
31 Dec 21 | 69 | -404 | 150 | 0 |
30 Sep 21 | 93 | -356 | 113 | 294 |
30 Jun 21 | 89 | -297 | 97 | 285 |
31 Mar 21 | 80 | -340 | 85 | 184 |
31 Dec 20 | 75 | -266 | 73 | 0 |
30 Sep 20 | 59 | -310 | 55 | 231 |
30 Jun 20 | 64 | -271 | 46 | 210 |
31 Mar 20 | 61 | -165 | 38 | 189 |
01 Jan 20 | 62 | -102 | 32 | 162 |
31 Dec 18 | 49 | -3 | 4 | 61 |
31 Dec 17 | 24 | 9 | 2 | 8 |
Quality Earnings: LEGN is currently unprofitable.
Growing Profit Margin: LEGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LEGN is unprofitable, and losses have increased over the past 5 years at a rate of 29.2% per year.
Accelerating Growth: Unable to compare LEGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LEGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: LEGN has a negative Return on Equity (-41.41%), as it is currently unprofitable.